How did Divi's Laboratories perform in the final quarter?

The company recorded revenue of ₹2,986 crore for the fourth quarter, an 11.8% increase over the same period last year.

What drove the performance in the fourth quarter?

Revenue growth included a contribution from foreign exchange gains of ₹90 crore. This is a nine-fold increase compared to the prior year.

How does the new dividend compare to the previous year?

The board recommended a final dividend of ₹30 per share. This is double the ₹15 per share payout from the previous year.

When is the annual general meeting scheduled?

The company set the annual general meeting for August 10.

Earnings · Pharmaceuticals

Divi's Laboratories lifts dividend to ₹30 as FY26 profit climbs 17%

The pharmaceutical major reported a 13.9% revenue increase to ₹11,067 crore. A surge in foreign exchange gains helped the final quarter.

DIVISLAB BSE 532488 25 May 2026 · 8:58 AM IST Verify on BSE · NSE

Mkt cap₹1.83 lakh cr

P/E71.19×

ROE14.64%

Debt / eq.0.00

Div yld0.44%

₹30 / share Final dividend recommended by the board, doubling the prior year's payout.

What's new

FY26 revenue hit ₹11,067 crore, a 13.9% year-on-year increase.
Net profit rose 17.2% to ₹2,568 crore for the full year.
Q4 revenue grew 11.8% to ₹2,986 crore, aided by ₹90 crore in forex gains.

Why this matters

The dividend hike to ₹30 per share from ₹15 shows the company has excess cash. The operational results match expectations, but the capital allocation shift provides a direct benefit to shareholders.

What we're watching

Sustainability of foreign exchange gains in future quarters.
Management commentary on cost structures during the August 10 AGM.
Capex plans for the coming fiscal year.

The full read

Divi's Laboratories closed FY26 with a 13.9% rise in consolidated revenue to ₹11,067 crore and a 17.2% jump in net profit to ₹2,568 crore. Cash is plentiful. The fourth quarter alone contributed ₹2,986 crore to that total, an 11.8% year-on-year increase. A nine-fold spike in foreign exchange gains added ₹90 crore to the quarterly result. The board doubled the final dividend to ₹30 per share from the previous year's ₹15. This move shows management is prioritizing direct shareholder returns. The company will hold its annual general meeting on August 10 to finalize these payouts.

Questions answered

How did Divi's Laboratories perform in the final quarter?: The company recorded revenue of ₹2,986 crore for the fourth quarter, an 11.8% increase over the same period last year.
What drove the performance in the fourth quarter?: Revenue growth included a contribution from foreign exchange gains of ₹90 crore. This is a nine-fold increase compared to the prior year.
How does the new dividend compare to the previous year?: The board recommended a final dividend of ₹30 per share. This is double the ₹15 per share payout from the previous year.
When is the annual general meeting scheduled?: The company set the annual general meeting for August 10.

Mentioned: Divi's Laboratories · August 10 AGM

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.